Antibody/Targeted-Drug Conjugates (ATDC) 2019

Antibody/Targeted-Drug Conjugates (ATDC) 2019 is organized by Meetings Management (Mm) and will be held from Nov 06 - 08, 2019 at Queen's University Belfast, Belfast, North Ireland, United Kingdom.

Conference Description:
The concept of using biologics and particles including monoclonal antibodies to deliver drugs to disease targets such as cancer cells has been explored for decades, with early work surrounding non-specific targets and drugs with low potencies. These studies highlighted the importance of critical parameters, such as antigen and tumor target selection, linker stability, drug potency, pharmacokinetics and conjugation methodology, in developing effectively targeted drug conjugates with acceptable safety/toxicity profiles.

The third ATDC New Developments & Updates conference to be held in Belfast, Northern Ireland, UK in November 2019 will aim to examine the concept and future of targeted drug delivery systems to include antibodies/bispecific antibodies/proteins/nanoparticles and other biologics.

Conference Scope and Topics:
• Novel ADC targets/ADC target discovery/target disease indications (including non-cancer targets)
• Novel payloads/modes of action (beyond tubulin binders)
• Biological components (antibody & antibody-like formats; molecularly defined conjugation sites)
• Chemical components: Linker/payload combinations; optimization of linker chemistry; cleavable linkers
• Next generation ADCs (site-specifically conjugated, including enzymatic conjugation
• Immunotoxins
• Chemistry approaches: mediating high toxicity of new warheads currently in use
• Chemical modifications of ADC structure and linkers
• Improving the therapeutic index – toxicity reduction efforts avoiding efficacy reduction
• Other carriers/delivery possibilities beyond antibodies and bispecific antibodies (nanoparticles, peptides, aptamers, hormones, and their analogs, small molecules, liposomes, vitamins)
• Manufacturing/Regulatory issues
• Process development (robustness, scalability)
• Clinical stage ADCs/ongoing clinical trials, clinical translation

Additional details will be posted as soon as they are available.